BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

AMENDMENTS TO THE CLAIMS

1. (CURRENTLY AMENDED) A compound of formula (I):



(I)

or stereoisomers or pharmaceutically acceptable salts thereof, wherein:

A is ~~selected from~~



;

G is selected from $-C(O)R^3$, $-C(O)NR^2R^3$, $-C(O)OR^3$, $-SO_2NR^2R^3$, $-SO_2R^3$, $-C(=S)NR^2R^3$, $C(=NR^{1a})NR^2R^3$, $C(=CHCN)NR^2R^3$, $C(=CHNO_2)NR^2R^3$, and

AMENDMENTS TO THE CLAIMS

$C(=C(CN)_2)NR^2R^3$,  ~~and~~  ;

W, at each occurrence, is independently selected from C or N, provided at least two of W are C;

X is ~~selected from~~ ~~O, S, and NR^{19}~~;

X^1 and X^2 are independently selected from C and N;

Z^1 is selected from C and N;

Z^2 is selected from NR^{1a}, O, S and C;

R^1 and R^2 are independently selected from H, C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, and a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^a;

R^{1a} is independently selected from H, C_{1-6} alkyl, $(CH_2)_rC_{3-6}$ cycloalkyl, and a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^a;

R^a, at each occurrence, is selected from C_{1-4} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, I, F, $(CF_2)_rCF_3$, NO_2, CN, $(CH_2)_rNR^bR^b$, $(CH_2)_rOH$, $(CH_2)_rOR^c$, $(CH_2)_rSH$, $(CH_2)_rSR^c$, $(CH_2)_rC(O)R^b$, $(CH_2)_rC(O)NR^bR^b$, $(CH_2)_rNR^bC(O)R^b$,

AMENDMENTS TO THE CLAIMS

$(CH_2)_rC(O)OR^b$, $(CH_2)_rOC(O)R^c$, $(CH_2)_rCH(=NR^b)NR^bR^b$, $(CH_2)_rNHC(=NR^b)NR^bR^b$, $(CH_2)_rS(O)_pR^c$, $(CH_2)_rS(O)_2NR^bR^b$, $(CH_2)_rNR^bS(O)_2R^c$, and $(CH_2)_r$phenyl;

R^b, at each occurrence, is selected from H, C_{1-6} alkyl, C_{3-6} cycloalkyl, and phenyl;

R^c, at each occurrence, is selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, and phenyl;

alternatively, R^2 and R^3 join to form a 5, 6, or 7-membered ring substituted with 0-3 R^a;

R^3 is selected from a $(CR^{3'}R^{3''})_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{15} and a $(CR^{3'}R^{3''})_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{15};

$R^{3'}$ and $R^{3''}$, at each occurrence, are selected from H, C_{1-6} alkyl, $(CH_2)_rC_{3-6}$ cycloalkyl, and phenyl;

R^4 is hydrogen, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, and a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^a;

alternatively, R^4 joins with R^8 or R^{11} to form a pyrrolidine or piperidine ring system substituted with 0-3 R^{4d};

AMENDMENTS TO THE CLAIMS

$R^{4'}$ is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{3-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, $(CH_2)_qC(O)R^{4b}$, $(CH_2)_qC(O)NR^{4a}R^{4a'}$, $(CH_2)_qC(O)OR^{4a}$, and a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-3 R^{4c};

R^{4a} and $R^{4a'}$, at each occurrence, are selected from H, C_{1-6} alkyl, $(CH_2)_rC_{3-6}$ cycloalkyl, and phenyl;

R^{4b}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, $(CH_2)_rC_{3-6}$ cycloalkyl, C_{2-8} alkynyl, and phenyl;

R^{4c}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-6} cycloalkyl, Cl, F, Br, I, CN, NO_2, $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, $(CH_2)_rOH$, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_rNR^{4a}R^{4a'}$, and $(CH_2)_r$phenyl;

R^{4d}, is selected from H, C_{1-6} alkyl, $(CHR')_qOH$, $(CHR')_qOR^{7a}$, $(CHR')_qOC(O)R^{7b}$, $(CHR')_qOC(O)NHR^{7a}$;

R^5 is selected from a $(CR^{5'}R^{5''})_t$-$C_{3-10310}$ carbocyclic residue substituted with 0-5 R^{1616} and a $(CR^{5'}R^{5''})$t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1616};

AMENDMENTS TO THE CLAIMS

$R^{5'}$ and $R^{5''}$, at each occurrence, are selected from H, C_{1-6} alkyl, $(CH_2)_rC_{3-6}$ cycloalkyl, and phenyl;

R^7, is selected from H, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CHR')_qOH$, $(CHR')_qSH$, $(CHR')_qOR^{7d}$, $(CHR')_qSR^{7d}$, $(CHR')_qNR^{7a}R^{7a'}$, $(CHR')_qC(O)OH$, $(CHR')_rC(O)R^{7b}$, $(CHR')_qC(O)NR^{7a}R^{7a'}$, $(CHR')_qNR^{7a}C(O)R^{7a}$, $(CHR')_qNR^{7a}C(O)H$, $(CHR')_qC(O)OR^{7a}$, $(CHR')_qOC(O)R^{7b}$, $(CHR')_qS(O)_pR^{7b}$, $(CHR')_qS(O)_2NR^{7a}R^{7a'}$, $(CHR')_qNR^{7a}S(O)_2R^{7b}$, $(CHR')_qNHC(O)NR^{7a'}R^{7a}$, $(CHR')_qNHC(O)OR^{7a}$, $(CHR')_qOC(O)NHR^{7a}$, C_{1-6} haloalkyl, a $(CHR')_r$-C_{3-10} carbocyclic residue substituted with 0-3 R^{7c}, and a $(CHR')_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{7c};

R^{7a} and $R^{7a'}$, at each occurrence, are selected from H, C_{1-6} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{7e}, and a $(CH_2)_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{7e};

R^{7b}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, a $(CH_2)_r$-C_{3-6} carbocyclic residue substituted with 0-2 R^{7e}, and a $(CH_2)_r$-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{7e};

AMENDMENTS TO THE CLAIMS

R^{7c}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, I, F, $(CF_2)_rCF_3$, NO_2, CN, $(CH_2)_rNR^{7f}R^{7f}$, $(CH_2)_rOH$, $(CH_2)_rOC_{1-4}$ alkyl, $(CH_2)_rSC_{1-4}$ alkyl, $(CH_2)_rC(O)OH$, $(CH_2)_rC(O)R^{7b}$, $(CH_2)_rC(O)NR^{7f}R^{7f}$, $(CH_2)_rNR^{7f}C(O)R^{7a}$, $(CH_2)_rC(O)OC_{1-4}$ alkyl, $(CH_2)_rOC(O)R^{7b}$, $(CH_2)_rC(=NR^{7f})NR^{7f}R^{7f}$, $(CH_2)_rS(O)_pR^{7b}$, $(CH_2)_rNHC(=NR^{7f})NR^{7f}R^{7f}$, $(CH_2)_rS(O)_2NR^{7f}R^{7f}$, $(CH_2)_rNR^{7f}S(O)_2R^{7b}$, and $(CH_2)_r$phenyl substituted with 0-3 R^{7e};

R^{7d}, at each occurrence, is selected from methyl, CF_3, C_{2-6} alkyl substituted with 0-3 R^{7e}, and a C_{3-10} carbocyclic residue substituted with 0-3 R^{7c};

R^{7e}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-6} cycloalkyl, Cl, F, Br, I, $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, $(CH_2)_qOH$, OH, $(CH_2)_qSH$, SH, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_qNR^{7f}R^{7f}$, and $(CH_2)_r$phenyl;

R^{7f}, at each occurrence, is selected from H, C_{1-6} alkyl, and C_{3-6} cycloalkyl;

R^8 is selected from H, C_{1-6} alkyl, C_{3-6} cycloalkyl, and $(CH_2)_r$phenyl substituted with 0-3 R^{8a};

AMENDMENTS TO THE CLAIMS

R^{8a}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-6} cycloalkyl, Cl, F, Br, I, CN, NO_2, $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, OH, SH, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_rNR^{7f}R^{7f}$, and $(CH_2)_r$phenyl;

alternatively, R^7 and R^8 join to form C_{3-7} cycloalkyl, or $=NR^{8b}$;

R^{8b} is selected from H, C_{1-6} alkyl, C_{3-6} cycloalkyl, OH, CN, and $(CH_2)_r$-phenyl;

R^{11}, is selected from H, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_qOH$, $(CH_2)_qSH$, $(CH_2)_qOR^{11d}$, $(CH_2)_qSR^{11d}$, $(CH_2)_qNR^{11a}R^{11a'}$, $(CH_2)_rC(O)OH$, $(CH_2)_rC(O)R^{11b}$, $(CH_2)_rC(O)NR^{11a}R^{11a'}$, $(CH_2)_qNR^{11a}C(O)R^{11b}$, $(CH_2)_qNR^{11a}C(O)NR^{11a'}R^{11a}$, $(CH_2)_rC(O)OR^{11a}$, $(CH_2)_qOC(O)R^{11b}$, $(CH_2)_qS(O)_pR^{11b}$, $(CH_2)_qS(O)_2NR^{11a}R^{11a'}$, $(CH_2)_qNR^{11a}S(O)_2R^{11b}$, C_{1-6} haloalkyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{11c}, and a $(CH_2)_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{11c};

R^{11a} and $R^{11a'}$, at each occurrence, are selected from H, C_{1-6} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{11e}, and a $(CH_2)_r$-5-10 membered heterocyclic system

containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{11e};

R^{11b}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, a $(CH_2)_r$-C_{3-6} carbocyclic residue substituted with 0-2 R^{11e}, and a $(CH_2)_r$-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{11e};

R^{11c}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, I, F, $(CF_2)_rCF_3$, NO_2, CN, $(CH_2)_rNR^{11f}R^{11f}$, $(CH_2)_rOH$, $(CH_2)_rOC_{1-4}$ alkyl, $(CH_2)_rSC_{1-4}$ alkyl, $(CH_2)_rC(O)OH$, $(CH_2)_rC(O)R^{11b}$, $(CH_2)_rC(O)NR^{11f}R^{11f}$, $(CH_2)_rNR^{11f}C(O)R^{11a}$, $(CH_2)_rC(O)OC_{1-4}$ alkyl, $(CH_2)_rOC(O)R^{11b}$, $(CH_2)_rC(=NR^{11f})NR^{11f}R^{11f}$, $(CH_2)_rNHC(=NR^{11f})NR^{11f}R^{11f}$, $(CH_2)_rS(O)_pR^{11b}$, $(CH_2)_rS(O)_2NR^{11f}R^{11f}$, $(CH_2)_rNR^{11f}S(O)_2R^{11b}$, and $(CH_2)_r$phenyl substituted with 0-3 R^{11e};

R^{11d}, at each occurrence, is selected from methyl, CF_3, C_{2-6} alkyl substituted with 0-3 R^{11e}, C_{3-6} alkenyl, C_{3-6} alkynyl, and a C_{3-10} carbocyclic residue substituted with 0-3 R^{11c};

R^{11e}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-6} cycloalkyl, Cl, F, Br, I, CN, NO_2, $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, OH,

AMENDMENTS TO THE CLAIMS

SH, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_rNR^{11f}R^{11f}$, and $(CH_2)_r$phenyl;

R^{11f}, at each occurrence, is selected from H, C_{1-6} alkyl, and C_{3-6} cycloalkyl;

R^{15}, at each occurrence, is selected from C_{1-8} alkyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, I, F, NO_2, CN, $(CHR')_rNR^{15a}R^{15a'}$, $(CHR')_rOH$, $(CHR')_rO(CHR')_rR^{15d}$, $(CHR')_rSH$, $(CHR')_rC(O)H$, $(CHR')_rS(CHR')_rR^{15d}$, $(CHR')_rC(O)OH$, $(CHR')_rC(O)(CHR')_rR^{15b}$, $(CHR')_rC(O)NR^{15a}R^{15a'}$, $(CHR')_rNR^{15f}C(O)(CHR')_rR^{15b}$, $(CHR')_rNR^{15f}C(O)NR^{15a}R^{15a'}$, $(CHR')_rC(O)O(CHR')_rR^{15d}$, $(CHR')_rOC(O)(CHR')_rR^{15b}$, $(CHR')_rC(=NR^{15f})NR^{15a}R^{15a'}$, $(CHR')_rNHC(=NR^{15f})NR^{15a}R^{15a'}$, $(CHR')_rS(O)_p(CHR')_rR^{15b}$, $(CHR')_rS(O)_2NR^{15a}R^{15a'}$, $(CHR')_rNR^{15f}S(O)_2(CHR')_rR^{15b}$, C_{1-6} haloalkyl, C_{2-8} alkenyl substituted with 0-3 R', C_{2-8} alkynyl substituted with 0-3 R', $(CHR')_r$phenyl substituted with 0-3 R^{15e}, and a $(CH_2)_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{15e};

R', at each occurrence, is selected from H, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, and $(CH_2)_r$phenyl substituted with R^{15e};

AMENDMENTS TO THE CLAIMS

R^{15a} and $R^{15a'}$, at each occurrence, are selected from H, C_{1-6} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{15e}, and a $(CH_2)_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{15e};

R^{15b}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, a $(CH_2)_r$-C_{3-6} carbocyclic residue substituted with 0-3 R^{15e}, and $(CH_2)_r$-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{15e};

R^{15d}, at each occurrence, is selected from C_{3-8} alkenyl, C_{3-8} alkynyl, methyl, CF_3, C_{2-6} alkyl substituted with 0-3 R^{15e}, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-3 R^{15e}, and a $(CH_2)_r$5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{15e};

R^{15e}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, F, Br, I, CN, NO_2, $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, OH, SH, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_rNR^{15f}R^{15f}$, and $(CH_2)_r$phenyl;

R^{15f}, at each occurrence, is selected from H, C_{1-6} alkyl, C_{3-6} cycloalkyl, and phenyl;

AMENDMENTS TO THE CLAIMS

R^{16}, at each occurrence, is selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, I, F, NO_2, CN, $(CHR')_rNR^{16a}R^{16a'}$, $(CHR')_rOH$, $(CHR')_rO(CHR')_rR^{16d}$, $(CHR')_rSH$, $(CHR')_rC(O)H$, $(CHR')_rS(CHR')_rR^{16d}$, $(CHR')_rC(O)OH$, $(CHR')_rC(O)(CHR')_rR^{16b}$, $(CHR')_rC(O)NR^{16a}R^{16a'}$, $(CHR')_rNR^{16f}C(O)(CHR')_rR^{16b}$, $(CHR')_rC(O)O(CHR')_rR^{16d}$, $(CHR')_rOC(O)(CHR')_rR^{16b}$, $(CHR')_rC(=NR^{16f})NR^{16a}R^{16a'}$, $(CHR')_rNHC(=NR^{16f})NR^{16a}R^{16a'}$, $(CHR')_rS(O)_p(CHR')_rR^{16b}$, $(CHR')_rS(O)_2NR^{16a}R^{16a'}$, $(CHR')_rNR^{16f}S(O)_2(CHR')_rR^{16b}$, C_{1-6} haloalkyl, C_{2-8} alkenyl substituted with 0-3 R', C_{2-8} alkynyl substituted with 0-3 R', and $(CHR')_r$phenyl substituted with 0-3 R^{16e};

R^{16a} and $R^{16a'}$, at each occurrence, are selected from H, C_{1-6} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{16e}, and a $(CH_2)_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{16e};

R^{16b}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, a $(CH_2)_rC_{3-6}$ carbocyclic residue substituted with 0-3 R^{16e}, and a $(CH_2)_r$-5-6 membered heterocyclic system containing 1-4

heteroatoms selected from N, O, and S, substituted with 0-2 R^{16e};

R^{16d}, at each occurrence, is selected from C_{3-8} alkenyl, C_{3-8} alkynyl, methyl, CF_3, C_{2-6} alkyl substituted with 0-3 R^{16e}, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-3 R^{16e}, and a $(CH_2)_r$-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{16e};

R^{16e}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, F, Br, I, CN, NO_2, $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, OH, SH, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_rNR^{16f}R^{16f}$, and $(CH_2)_r$phenyl;

R^{16f}, at each occurrence, is selected from H, C_{1-5} alkyl, and C_{3-6} cycloalkyl, and phenyl;

R^{17}, is selected from H, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_qOH$, $(CH_2)_qSH$, $(CH_2)_qOR^{17d}$, $(CH_2)_qSR^{17d}$, $(CH_2)_qNR^{17a}R^{17a'}$, $(CH_2)_rC(O)OH$, $(CH_2)_rC(O)R^{17b}$, $(CH_2)_rC(O)NR^{17a}R^{17a'}$, $(CH_2)_qNR^{17a}C(O)R^{17b}$, $(CH_2)_qNR^{17a}C(O)H$, $(CH_2)_rC(O)OR^{17a}$, $(CH_2)_qOC(O)R^{17b}$, $(CH_2)_qS(O)_pR^{17b}$, $(CH_2)_qS(O)_2NR^{17a}R^{17a'}$, $(CH_2)_qNR^{17a}S(O)_2R^{17b}$, C_{1-6} haloalkyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-3 R^{17c}, and a $(CH_2)_r$-5-10 membered heterocyclic system containing 1-4

heteroatoms selected from N, O, and S, substituted with 0-2 R^{17c};

R^{17a} and $R^{17a'}$, at each occurrence, are selected from H, C_{1-6} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{17e}, and a $(CH_2)_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{17e};

R^{17b}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, a $(CH_2)_r$-C_{3-6} carbocyclic residue substituted with 0-2 R^{17e}, and a $(CH_2)_r$-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{17e};

R^{17c}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, I, F, $(CF_2)_rCF_3$, NO_2, CN, $(CH_2)_rNR^{17f}R^{17f}$, $(CH_2)_rOH$, $(CH_2)_rOC_{1-4}$ alkyl, $(CH_2)_rSC_{1-4}$ alkyl, $(CH_2)_rC(O)OH$, $(CH_2)_rC(O)R^{17b}$, $(CH_2)_rC(O)NR^{17f}R^{17f}$, $(CH_2)_rNR^{17f}C(O)R^{17a}$, $(CH_2)_rC(O)OC_{1-4}$ alkyl, $(CH_2)_rOC(O)R^{17b}$, $(CH_2)_rC(=NR^{17f})NR^{17f}R^{17f}$, $(CH_2)_rS(O)_pR^{17b}$, $(CH_2)_rNHC(=NR^{17f})NR^{17f}R^{17f}$, $(CH_2)_rS(O)_2NR^{17f}R^{17f}$, $(CH_2)_rNR^{17f}S(O)_2R^{17b}$, and $(CH_2)_r$phenyl substituted with 0-3 R^{17e};

R^{17d}, at each occurrence, is selected from methyl, CF_3, C_{2-6} alkyl substituted with 0-3 R^{17e}, C_{3-6} alkenyl,

C_{3-6} alkynyl, and a C_{3-10} carbocyclic residue substituted with 0-3 R^{17c};

R^{17e}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-6} cycloalkyl, Cl, F, Br, I, CN, NO_2, $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, OH, SH, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_rNR^{17f}R^{17f}$, and $(CH_2)_r$phenyl;

R^{17f}, at each occurrence, is selected from H, C_{1-6} alkyl, and C_{3-6} cycloalkyl;

R^{18}, is selected from H, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CHR')_qOH$, $(CHR')_qSH$, $(CHR')_qOR^{18d}$, $(CHR')_qSR^{18d}$, $(CHR')_qNR^{18a}R^{18a'}$, $(CHR')_rC(O)OH$, $(CHR')_rC(O)R^{18b}$, $(CHR')_rC(O)NR^{18a}R^{18a'}$, $(CHR')_qNR^{18a}C(O)R^{18a}$, $(CHR')_qNR^{18a}C(O)H$, $(CHR')_rC(O)OR^{18a}$, $(CHR')_qOC(O)R^{18b}$, $(CHR')_qS(O)_pR^{18b}$, $(CHR')_qS(O)_2NR^{18a}R^{18a'}$, $(CHR')_qNR^{18a}S(O)_2R^{18b}$, C_{1-6} haloalkyl, a $(CHR')_r$-C_{3-10} carbocyclic residue substituted with 0-3 R^{18c}, and a $(CHR')_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{18c};

R^{18a} and $R^{18a'}$, at each occurrence, are selected from H, C_{1-6} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{18e}, and a $(CH_2)_r$-5-10 membered heterocyclic

system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{18e};

R^{18b}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, a $(CH_2)_r$-C_{3-6} carbocyclic residue substituted with 0-2 R^{18e}, and a $(CH_2)_r$-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{18e};

R^{18c}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, I, F, $(CF_2)_rCF_3$, NO_2, CN, $(CH_2)_rNR^{18f}R^{18f}$, $(CH_2)_rOH$, $(CH_2)_rOC_{1-4}$ alkyl, $(CH_2)_rSC_{1-4}$ alkyl, $(CH_2)_rC(O)OH$, $(CH_2)_rC(O)R^{18b}$, $(CH_2)_rC(O)NR^{18f}R^{18f}$, $(CH_2)_rNR^{18f}C(O)R^{18a}$, $(CH_2)_rC(O)OC_{1-4}$ alkyl, $(CH_2)_rOC(O)R^{18b}$, $(CH_2)_rC(=NR^{18f})NR^{18f}R^{18f}$, $(CH_2)_rS(O)_pR^{18b}$, $(CH_2)_rNHC(=NR^{18f})NR^{18f}R^{18f}$, $(CH_2)_rS(O)_2NR^{18f}R^{18f}$, $(CH_2)_rNR^{18f}S(O)_2R^{18b}$, and $(CH_2)_r$phenyl substituted with 0-3 R^{18e};

R^{18d}, at each occurrence, is selected from methyl, CF_3, C_{2-6} alkyl substituted with 0-3 R^{18e}, C_{3-6} alkenyl, C_{3-6} alkynyl, and a C_{3-10} carbocyclic residue substituted with 0-3 R^{18c};

R^{18e}, at each occurrence, is selected from C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-6} cycloalkyl, Cl, F, Br, I, CN, NO_2, $(CF_2)_rCF_3$, $(CH_2)_rOC_{1-5}$ alkyl, OH,

AMENDMENTS TO THE CLAIMS

SH, $(CH_2)_rSC_{1-5}$ alkyl, $(CH_2)_rNR^{18f}R^{18f}$, and $(CH_2)_r$phenyl;

R^{18f}, at each occurrence, is selected from H, C_{1-6} alkyl, and C_{3-6} cycloalkyl;

R^{19} is selected from C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, $-C(O)R^{19b}$, $-C(O)NR^{19a}R^{19a}$, $-C(O)OR^{19a}$, and $-SO_2R^{19a}$, a $(CHR')_r$-C_{3-10} carbocyclic residue substituted with 0-3 R^{16}, and a $(CHR')_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{16};

R^{19a} is selected from C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, C_{3-6} cycloalkyl, a $(CR^{5'}R^{5''})_t$-C_{3-10} carbocyclic residue substituted with 0-5 R^{15} and a $(CR^{5'}R^{5''})_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{16};

R^{19b} is selected from H, C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-8} alkynyl, C_{3-6} cycloalkyl, a $(CR^{5'}R^{5''})_t$-C_{3-10} carbocyclic residue substituted with 0-5 R^{15} and a $(CR^{5'}R^{5''})_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{16};

m, at each occurrence, is selected from 1, 2, 3, 4, and 5;

n, at each occurrence, is selected from 0, 1, 2, 3, 4, and 5;

o, at each occurrence, is selected from 1 and 2;

p, at each occurrence, is selected from 1 and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, 4, and 5;

q, at each occurrence, is selected from 1, 2, 3, 4, and 5;

s, at each occurrence, is selected from 0, 1, and 2;

t, at each occurrence, is selected from 0, 1, 2, 3, 4, and 5;

u, at each occurrence, is independently selected from 0, 1, and 2;

v, at each occurrence, is selected from 0 and 1; and

w, at each occurrence, is selected from 0, 1, 2, and 3.

2. (ORIGINAL) The compound of claim 1, wherein:

$R^{4'}$ is absent or, taken with the nitrogen to which it is attached to form an N-oxide;

AMENDMENTS TO THE CLAIMS

R^7, is selected from H, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CHR')_qOH$, $(CHR')_qOR^{7d}$, $(CHR')_qNR^{7a}R^{7a'}$, $(CHR')_qC(O)R^{7b}$, $(CHR')_qC(O)NR^{7a}R^{7a'}$, $(CHR')_qNR^{7a}C(O)R^{7b}$, $(CHR')_qNR^{7a}C(O)H$, $(CHR')_qS(O)_2NR^{7a}R^{7a'}$, $(CHR')_qNR^{7a}S(O)_2R^{7b}$, $(CHR')_qNHC(O)NHR^{7a}$, $(CHR')_qNHC(O)OR^{7a}$, $(CHR')_qOC(O)NHR^{7a}$, C_{1-6} haloalkyl, a $(CHR')_r$-C_{3-10} carbocyclic residue substituted with 0-3 R^{7c}, and a $(CHR')_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{7c};

alternatively, R^7 and R^8 join to form C_{3-7} cycloalkyl, or $=NR^{8b}$;

R^{11}, is selected from H, C_{1-6} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_qOH$, $(CH_2)_qOR^{11d}$, $(CH_2)_qNR^{11a}R^{11a'}$, $(CH_2)_rC(O)R^{11b}$, $(CH_2)_rC(O)NR^{11a}R^{11a'}$, $(CH_2)_qNR^{11a}C(O)R^{11b}$, $(CH_2)_qNR^{11a}C(O)NHR^{11a}$, $(CH_2)_qNHC(O)NHR^{11a}$, $(CH_2)_qNHC(O)OR^{11a}$, $(CH_2)_qOC(O)NHR^{11a}$, C_{1-6} haloalkyl, a $(CH_2)_r$-C_{3-10} carbocyclic residue substituted with 0-5 R^{11c}, and a $(CH_2)_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{11c}.

3. (CURRENTLY AMENDED) The compound of claim 2, wherein:

A is ~~selected from~~

AMENDMENTS TO THE CLAIMS





~~and~~

; and

t is selected from 0, 1, and 2.

4. (ORIGINAL) The compound of claim 3, wherein:

R^{17} is selected from H; and

R^{18} is selected from H.

5. (CURRENTLY AMENDED) The compound of claim 4, wherein:

A is ~~selected from~~



~~and~~

6. (CURRENTLY AMENDED) The compound of claim 5, wherein:

G is selected from $-C(O)R^3$, $-C(O)NR^2R^3$, $-C(O)OR^3$, $-SO_2NR^2R^3$, and $-SO_2R^3$, $-C(=S)NR^2R^3$, $C(=NR^{1a})NR^2R^3$,

AMENDMENTS TO THE CLAIMS

$C(=CHCN)NR^2R^3$, $C(=CHNO_2)NR^2R^3$, and



$C(=C(CN)_2)NR^2R^3$~~, and~~ .

7. (CURRENTLY AMENDED) The compound of claim 6, wherein:

G is selected from $-C(O)NR^2R^3$, ~~$^{23}C(=NR^{1a})NR^2R^3$,~~ $C(=NR^{1a})NR^2R^3$, $C(=CHCN)NR^2R^3$, $C(=CHNO_2)NR^2R^3$, and $C(=C(CN)_2)NR^2R^3$~~,~~.

8. (ORIGINAL) The compound of claim 7, wherein:

R^{16}, at each occurrence, is selected from methyl, ethyl, propyl, iso-propyl, C_{2-8} alkenyl, C_{2-8} alkynyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, I, F, NO_2, CN, $(CHR')_rNR^{16a}R^{16a'}$, $(CHR')_rOH$, $(CHR')_rO(CHR')_rR^{16d}$, $(CHR')_rC(O)(CHR')_rR^{16b}$, $(CHR')_rC(O)NR^{16a}R^{16a'}$, $(CHR')_rNR^{16f}C(O)(CHR')_rR^{16b}$, $(CHR')_rS(O)_p(CHR')_rR^{16b}$, $(CHR')_rS(O)_2NR^{16a}R^{16a'}$, $(CHR')_rNR^{16f}S(O)_2(CHR')_rR^{16b}$, C_{1-6} haloalkyl, and $(CHR')_r$phenyl substituted with 0-3 R^{16e};

R^{16a} and $R^{16a'}$, at each occurrence, are selected from H, methyl, ethyl, and a $(CH_2)_r$-C_{3-6} carbocyclic residue substituted with 0-2 R^{16e};

AMENDMENTS TO THE CLAIMS

R^{16e}, at each occurrence, is selected from methyl, ethyl, Cl, F, Br, I, CN, CF_3, and OCH_3;

R^{16f}, at each occurrence, is selected from H; and

r is selected from 0, 1, and 2.

9. (CURRENTLY AMENDED) The compound of claim 8, wherein:

R^3 is selected from a $(CR^{3'}R^{3''})_r$-C_{3-6} carbocyclic residue substituted with 0-2 R^{15} and a $(CR^{3'}CR^{3''})_r$-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, ~~subsituted~~ substituted with 0-2 R^{15};

$R^{3'}$ and $R^{3''}$, at each occurrence, are selected from H;

R^{15}, at each occurrence, is selected from C_{1-8} alkyl, $(CH_2)_rC_{3-6}$ cycloalkyl, Cl, Br, F, CN, $(CHR')_rNR^{15a}R^{15a'}$, $(CHR')_rOH$, $(CHR')_rO(CHR')_rR^{15d}$, $(CHR')_rC(O)(CHR')_rR^{15b}$, $(CHR')_rC(O)NR^{15a}R^{15a'}$, $(CHR')_rNR^{15f}C(O)(CHR')_rR^{15b}$, $(CHR')_rNR^{15f}C(O)NR^{15f}R^{15f}$, $(CHR')_rC(O)O(CHR')_rR^{15d}$, $(CHR')_rOC(O)(CHR')_rR^{15b}$, $(CHR')_rS(O)_p(CHR')_rR^{15b}$, $(CHR')_rS(O)_2NR^{15a}R^{15a'}$, $(CHR')_rNR^{15f}S(O)_2(CHR')_rR^{15b}$, C_{1-6} haloalkyl, C_{2-8} alkenyl substituted with 0-3 R', C_{2-8} alkynyl substituted with 0-3 R', $(CHR')_r$phenyl substituted with 0-3 R^{15e}, and a $(CH_2)_r$-5-10 membered heterocyclic system

containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R^{15e};

R', at each occurrence, is selected from H, and C_{1-6} alkyl;

R^{15a} and $R^{15a'}$, at each occurrence, are selected from H, C_{1-6} alkyl, a $(CH_2)_r$-C_{3-6} carbocyclic residue substituted with 0-5 R^{15e}, and a $(CH_2)_r$-5-6 membered heterocyclic system containing 1-2 heteroatoms selected from N, O, and S, substituted with 0-2 R^{15e};

R^{15b}, at each occurrence, is selected from C_{1-6} alkyl, a $(CH_2)_r$-C_{3-6} carbocyclic residue substituted with 0-3 R^{15e}, and $(CH_2)_r$-5-6 membered heterocyclic system containing 1-2 heteroatoms selected from N, O, and S, substituted with 0-2 R^{15e}; and

R^{15e}, at each occurrence, is selected from C_{1-6} alkyl, Cl, F, Br, I, CN, $(CF_2)_rCF_3$, and OH.

10. (CANCELED)

11. (CANCELED)

12. (CANCELED)

13. (CANCELED)

14. (CANCELED)

AMENDMENTS TO THE CLAIMS

15. (CANCELED)

16. (CANCELED)

17. (CANCELED)

18. (CANCELED)

19. (CANCELED)

20. (CANCELED)

21. (CANCELED)

22. (CANCELED)

23. (CURRENTLY AMENDED) The compound of claim 1 wherein the compound is selected from:

~~*N*-(3-acetylphenyl)-*N'*-[(2*R*)-2-[[*cis*-4-[(4-fluorophenyl)methyl]-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea hydrochloride;~~

~~*N*-(3-acetylphenyl)-*N'*-[(2*R*)-2-[[*trans*-4-[(4-fluorophenyl)methyl]-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea hydrochloride;~~

~~*N*-(3-cyanophenyl)-*N'*-[(2*R*)-2-[[*trans*-4-[(4-fluorophenyl)methyl]-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea trifluoroacetate;~~

AMENDMENTS TO THE CLAIMS

~~*N*-(3-cyanophenyl)-*N'*-[(2*R*)-2-[[*cis*-4-[(4-fluorophenyl)methyl]-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea trifluoroacetate;~~

~~*N*-(3-cyanophenyl)-*N'*-[(2*S*)-2-[[*trans*-4-[(4-fluorophenyl)methyl]-1-cyclohexyl]amino]-(1*S*)-1-cyclohexyl]urea trifluoroacetate;~~

~~*N*-(3-cyanophenyl)-*N'*-[(2*S*)-2-[[*cis*-4-[(4-fluorophenyl)methyl]-1-cyclohexyl]amino]-(1*S*)-1-cyclohexyl]urea trifluoroacetate;~~

~~*N*-(3-acetylphenyl)-*N'*-[(2*S*)-2-[[*trans*-4-[(4-fluorophenyl)methyl]-1-cyclohexyl]amino]-(1*S*)-1-cyclohexyl]urea trifluoroacetate;~~

~~*N*-(3-acetylphenyl)-*N'*-[(2*S*)-2-[[*cis*-4-[(4-fluorophenyl)methyl]-1-cyclohexyl]amino]-(1*S*)-1-cyclohexyl]urea trifluoroacetate;~~

~~*N*-(3-acetylphenyl)-*N'*-[(2*R*)-2-[[(3*R*)-3-[(4-fluorophenyl)methyl]-(1*R*)-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea;~~

~~*N*-(3-acetylphenyl)-*N'*-[(2*R*)-2-[[(3*R*)-3-[(4-fluorophenyl)methyl]-(1*S*)-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea;~~

~~*N*-(3-acetylphenyl)-*N'*-[(2*R*)-2-[[(3*S*)-3-[(4-fluorophenyl)methyl]-(1*R*)-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea;~~

AMENDMENTS TO THE CLAIMS

~~*N*-(3-acetylphenyl)-*N'*-[(2*R*)-2-[[(3*S*)-3-[(4-fluorophenyl)methyl]-(1*S*)-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea;~~

~~*N*-(4-fluorophenyl)-*N'*-[(2*R*)-2-[[(3*R*)-3-[(4-fluorophenyl)methyl]-(1*R*)-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea;~~

~~*N*-(4-fluorophenyl)-*N'*-[(2*R*)-2-[[(3*R*)-3-[(4-fluorophenyl)methyl]-(1*S*)-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea;~~

~~*N*-(4-fluorophenyl)-*N'*-[(2*R*)-2-[[(3*S*)-3-[(4-fluorophenyl)methyl]-(1*R*)-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea;~~

~~*N*-(4-fluorophenyl)-*N'*-[(2*R*)-2-[[(3*S*)-3-[(4-fluorophenyl)methyl]-(1*S*)-1-cyclohexyl]amino]-(1*R*)-1-cyclohexyl]urea;~~

N-(3-acetylphenyl)-*N'*-((3*S*,4*S*)-4-{[4-(4-fluorobenzyl)cyclohexyl]amino}tetrahydro-3-furanyl)urea~~;~~.

~~*N*-(3-acetylphenyl)-*N'*-({(2*S*)-1-[4-(4-fluorobenzyl)cyclohexyl]pyrrolidinyl}methyl)urea;~~

~~*N*-(3-acetylphenyl)-*N'*-({(2*S*)-1-[4-(4-fluorobenzyl)cyclohexyl]pyrrolidinyl}methyl)urea;~~

~~*N*-(3-acetylphenyl)-*N'*-({(2*R*)-1-[4-(4-fluorobenzyl)cyclohexyl]pyrrolidinyl}methyl)urea;~~

~~*N*-(3-acetylphenyl)-*N*'-({(2*R*)-1-[4-(4-fluorobenzyl)cyclohexyl]pyrrolidinyl}methyl)urea;~~

~~*N*-(3-acetylphenyl)-*N*'-{(3*R*)-1-[4-(4-fluorobenzyl)cyclohexyl]pyrrolidinyl}urea;~~

~~*N*-(3-acetylphenyl)-*N*'-{(3*R*)-1-[4-(4-fluorobenzyl)cyclohexyl]pyrrolidinyl}urea;~~

~~*N*-(3-acetylphenyl)-*N*'-{(3*S*)-1-[4-(4-fluorobenzyl)cyclohexyl]pyrrolidinyl}urea; and~~

~~*N*-(3-acetylphenyl)-*N*'-{(3*S*)-1-[4-(4-fluorobenzyl)cyclohexyl]pyrrolidinyl}urea.~~

24. (ORIGINAL) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

25. (ORIGINAL) A method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

26. (ORIGINAL) A method for treating or preventing inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

AMENDMENTS TO THE CLAIMS

27. (ORIGINAL) A method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

28. (NEW) A pharmaceutical composition, comprising a pharamaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 9.

29. (NEW) A method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 9.

30. (NEW) A method for treating inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 9.

31. (NEW) A method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 9.

32. (NEW) A method according to Claim 30, wherein the disorder is selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, allergic colitis, eczema, conjunctivitis, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, and eosinophilic gastroenteritis.

33. (NEW) The method according to Claim 32, wherein the disorder is allergic rhinitis.

34. (NEW) The method according to Claim 32, wherein the disorder is atopic dermatitis.

35. (NEW) The method according to Claim 32, wherein the disorder is inflammatory bowel diseases.